logo-loader
viewOncimmune

Winner of BioNewsRound Award

/**/ sup{font-size:80%}h1{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Arial","sans-serif";color:#2F5496;font-weight:normal;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .ae{size:595.05pt 840.85pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ae{}p.al{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold}span.aj{background:white}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";}p.am{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: center}p.an{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";text-align:justify}p.ao{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify} /**/
RNS Number : 7215W
Oncimmune Holdings PLC
12 December 2019
 

12 December 2019

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Winner of BioNewsRound Award by One Nucleus

 

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, is pleased to announce it has received the BioNewsRound Award by One Nucleus which identifies life science companies that have announced exciting developments for patients and the sector over the past year.

 

The award, which recognises the ground-breaking potential of Oncimmune's EarlyCDT® Lung test and its use in the Early Detection of Cancer of the Lung Scotland ("ECLS") trial, was presented at Genesis 2019.

                                                                                        

-Ends-

 

For further information:

Oncimmune Holdings plc

 

Matthew Hall, Chief Financial Officer

[email protected]

 

Cléa Rosenfeld, Head of Investor Relations

[email protected]  

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[email protected]

+44 (0)20 3727 1000

 

About Oncimmune

 

Beating cancer, one test at a time

 

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both autoimmune disease and immuno-oncology. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

 

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT® Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

 

What is EarlyCDT Lung?

 

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

 

For more information, visit www.oncimmune.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAGGGWUPUPBGCP

Quick facts: Oncimmune

Price: 37.27

Market: AIM
Market Cap: £23.57 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

on 1/11/19